Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
•
Medical Oncology
What adjuvant therapy would you use for a young patient with stage IIIB high grade ESS s/p optimal debulking?
Any centers with trials available?
Related Questions
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?
What is your preferred first line systemic treatment for recurrent, metastatic, low grade, ER/PR+ pMMR endometrioid endometrial carcinoma?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
Do you use maintenance bevacizumab in addition to immunotherapy after 1st line chemotherapy + immunotherapy + bevacizumab in metastatic cervical squamous cell carcinoma?
Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?
